Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

Victor H. Jimenez-Zepeda, Joseph R Mikhael, Andrew Winter, Norman Franke, Esther Masih-Khan, Suzanne Trudel, Christine Chen, Vishal Kukreti, Donna E. Reece

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the availability of novel agents to treat progressive multiple myeloma (MM). We retrospectively reviewed all MM patients who received a second ASCT as salvage therapy at our center from March 1992 to December 2009. Eighty-one MM patients received a second ASCT for relapsed MM. The median time to relapse after first transplant was 39 months (9.83-100). All patients received reinduction therapy before the second ASCT. The high-dose regimen given before the second ASCT consisted of melphalan (MEL) alone in the majority. Complete response, very good partial response, and partial response were seen in 7.7%, 39.7%, and 50%, respectively, at day 100 post-ASCT; the median time to relapse after the second ASCT was 19 months. Early deaths occurred in 2.6%. Median progression-free survival (PFS) based on the time to myeloma relapse after first ASCT was 9.83 months (relapse ≤24 months) and 17.3 months (relapse ≥24 months) (P < .05). Median overall survival (OS) was 28.47 months (relapse ≤24 months) and 71.3 months (relapse >24 months) (P = .006). Second ASCT is a feasible and safe option for salvage therapy in MM. The best outcome was observed in patients whose time to progression was >24 months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years.

Original languageEnglish (US)
Pages (from-to)773-779
Number of pages7
JournalBiology of Blood and Marrow Transplantation
Volume18
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Salvage Therapy
Stem Cell Transplantation
Multiple Myeloma
Disease-Free Survival
Stem Cells
Transplants
Recurrence
Melphalan

Keywords

  • Autologous stem cell transplant (ASCT)
  • Multiple myeloma (MM)
  • Overall survival (OS)
  • Progression-free survival (PFS)
  • Salvage therapy

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma : Impact on Progression-Free and Overall Survival. / Jimenez-Zepeda, Victor H.; Mikhael, Joseph R; Winter, Andrew; Franke, Norman; Masih-Khan, Esther; Trudel, Suzanne; Chen, Christine; Kukreti, Vishal; Reece, Donna E.

In: Biology of Blood and Marrow Transplantation, Vol. 18, No. 5, 05.2012, p. 773-779.

Research output: Contribution to journalArticle

Jimenez-Zepeda, VH, Mikhael, JR, Winter, A, Franke, N, Masih-Khan, E, Trudel, S, Chen, C, Kukreti, V & Reece, DE 2012, 'Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival', Biology of Blood and Marrow Transplantation, vol. 18, no. 5, pp. 773-779. https://doi.org/10.1016/j.bbmt.2011.10.044
Jimenez-Zepeda, Victor H. ; Mikhael, Joseph R ; Winter, Andrew ; Franke, Norman ; Masih-Khan, Esther ; Trudel, Suzanne ; Chen, Christine ; Kukreti, Vishal ; Reece, Donna E. / Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma : Impact on Progression-Free and Overall Survival. In: Biology of Blood and Marrow Transplantation. 2012 ; Vol. 18, No. 5. pp. 773-779.
@article{95cdf0c1da6b42c197ae18556a96253c,
title = "Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival",
abstract = "The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the availability of novel agents to treat progressive multiple myeloma (MM). We retrospectively reviewed all MM patients who received a second ASCT as salvage therapy at our center from March 1992 to December 2009. Eighty-one MM patients received a second ASCT for relapsed MM. The median time to relapse after first transplant was 39 months (9.83-100). All patients received reinduction therapy before the second ASCT. The high-dose regimen given before the second ASCT consisted of melphalan (MEL) alone in the majority. Complete response, very good partial response, and partial response were seen in 7.7{\%}, 39.7{\%}, and 50{\%}, respectively, at day 100 post-ASCT; the median time to relapse after the second ASCT was 19 months. Early deaths occurred in 2.6{\%}. Median progression-free survival (PFS) based on the time to myeloma relapse after first ASCT was 9.83 months (relapse ≤24 months) and 17.3 months (relapse ≥24 months) (P < .05). Median overall survival (OS) was 28.47 months (relapse ≤24 months) and 71.3 months (relapse >24 months) (P = .006). Second ASCT is a feasible and safe option for salvage therapy in MM. The best outcome was observed in patients whose time to progression was >24 months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years.",
keywords = "Autologous stem cell transplant (ASCT), Multiple myeloma (MM), Overall survival (OS), Progression-free survival (PFS), Salvage therapy",
author = "Jimenez-Zepeda, {Victor H.} and Mikhael, {Joseph R} and Andrew Winter and Norman Franke and Esther Masih-Khan and Suzanne Trudel and Christine Chen and Vishal Kukreti and Reece, {Donna E.}",
year = "2012",
month = "5",
doi = "10.1016/j.bbmt.2011.10.044",
language = "English (US)",
volume = "18",
pages = "773--779",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma

T2 - Impact on Progression-Free and Overall Survival

AU - Jimenez-Zepeda, Victor H.

AU - Mikhael, Joseph R

AU - Winter, Andrew

AU - Franke, Norman

AU - Masih-Khan, Esther

AU - Trudel, Suzanne

AU - Chen, Christine

AU - Kukreti, Vishal

AU - Reece, Donna E.

PY - 2012/5

Y1 - 2012/5

N2 - The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the availability of novel agents to treat progressive multiple myeloma (MM). We retrospectively reviewed all MM patients who received a second ASCT as salvage therapy at our center from March 1992 to December 2009. Eighty-one MM patients received a second ASCT for relapsed MM. The median time to relapse after first transplant was 39 months (9.83-100). All patients received reinduction therapy before the second ASCT. The high-dose regimen given before the second ASCT consisted of melphalan (MEL) alone in the majority. Complete response, very good partial response, and partial response were seen in 7.7%, 39.7%, and 50%, respectively, at day 100 post-ASCT; the median time to relapse after the second ASCT was 19 months. Early deaths occurred in 2.6%. Median progression-free survival (PFS) based on the time to myeloma relapse after first ASCT was 9.83 months (relapse ≤24 months) and 17.3 months (relapse ≥24 months) (P < .05). Median overall survival (OS) was 28.47 months (relapse ≤24 months) and 71.3 months (relapse >24 months) (P = .006). Second ASCT is a feasible and safe option for salvage therapy in MM. The best outcome was observed in patients whose time to progression was >24 months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years.

AB - The role of a second autologous stem cell transplant (ASCT) as salvage therapy is unclear, particularly with the availability of novel agents to treat progressive multiple myeloma (MM). We retrospectively reviewed all MM patients who received a second ASCT as salvage therapy at our center from March 1992 to December 2009. Eighty-one MM patients received a second ASCT for relapsed MM. The median time to relapse after first transplant was 39 months (9.83-100). All patients received reinduction therapy before the second ASCT. The high-dose regimen given before the second ASCT consisted of melphalan (MEL) alone in the majority. Complete response, very good partial response, and partial response were seen in 7.7%, 39.7%, and 50%, respectively, at day 100 post-ASCT; the median time to relapse after the second ASCT was 19 months. Early deaths occurred in 2.6%. Median progression-free survival (PFS) based on the time to myeloma relapse after first ASCT was 9.83 months (relapse ≤24 months) and 17.3 months (relapse ≥24 months) (P < .05). Median overall survival (OS) was 28.47 months (relapse ≤24 months) and 71.3 months (relapse >24 months) (P = .006). Second ASCT is a feasible and safe option for salvage therapy in MM. The best outcome was observed in patients whose time to progression was >24 months after first ASCT, as these patients had a subsequent PFS lasting over 1 year and an OS of almost 6 years.

KW - Autologous stem cell transplant (ASCT)

KW - Multiple myeloma (MM)

KW - Overall survival (OS)

KW - Progression-free survival (PFS)

KW - Salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=84859851602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859851602&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2011.10.044

DO - 10.1016/j.bbmt.2011.10.044

M3 - Article

C2 - 22062804

AN - SCOPUS:84859851602

VL - 18

SP - 773

EP - 779

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 5

ER -